Leukemia, a type of cancer that affects the blood, is known for being especially tough to treat.
Acute Myeloid Leukemia (AML), a rapid and severe form of the disease, is particularly prevalent among adults, and unfortunately, it doesn’t respond well to current treatments.
With only about 29% of people surviving for five years or more after being diagnosed, the medical community has been hard at work trying to find better ways to combat it.
A dedicated team of researchers from Oslo and Stockholm may have found a glimmer of hope in this grim scenario.
Led by Professor Johanna Olweus in Oslo and collaborating with research groups headed by Professor Sten Eirik Jacobsen and researcher Petter Woll in Stockholm, they’ve uncovered a new approach that might change the game for AML treatment.
Unpacking the Innovative Approach
So, what’s this new treatment all about? In simple terms, our immune system uses cells (known as T cells) to fight off illnesses and infections.
The research team has found a way to use these fighter cells against AML. But let’s dig a bit deeper to understand how they did it.
Cancer cells are tricky; they mutate, which means they change in ways that often let them hide from our body’s natural defenses.
In the past, scientists believed that using immunotherapy (a kind of treatment that helps our immune system fight diseases better) could be aimed at these mutations, thereby making it a tool against cancer.
But the problem was that most of these mutations are so unique to each patient that creating a “one-size-fits-all” treatment was virtually impossible.
However, Olweus and her team noticed that some mutations weren’t so unique – they were shared among subgroups of patients.
They turned their attention to one particular gene, FLT3, which is often mutated in AML and speeds up the disease’s progression.
After some intensive research and with the help of technology developed in their lab, they discovered a T-cell receptor that could recognize this mutation.
Promising Results and Future Steps
Finding this receptor was a bit like discovering a secret door that lets the T cells into the cancer cells’ hiding place.
They tested their theory using advanced experiments involving mice and human leukemia cells, which were performed at the Karolinska Institutet in Stockholm, showing that it worked: the T cells, armed with the new receptor, were effectively destroying the leukemia cells.
What’s even more promising is that these T cells were able to kill cells that have characteristics of leukemia stem cells – a vital step in stopping the disease in its tracks.
This breakthrough, although still in its early stages, represents a promising stride towards new AML treatments.
Not only does it open up potential avenues for dealing with leukemia, but it also shines a light on how similar methods might be applied to other cancers in the future.
While the science behind it is complex, the aim of the research team is quite straightforward: to create a treatment that can be used to help as many patients as possible, bypassing the issue of having to customize it for each individual’s unique cancer mutations.
The journey from this discovery to a widely-available treatment will be a challenging one, involving further studies, clinical trials, and a great deal of collaboration across the scientific community.
But the hope and potential it brings into the fight against AML, and possibly other cancers, are truly invaluable.
The researchers are optimistic but cautious, aware that there is a long road ahead to bring this discovery from the laboratory to the hospital.
Nonetheless, this collaboration, hailed by Olweus as “fantastic” and spanning many years, has taken a monumental step forward in the battle against a formidable disease, providing a foundation upon which future cancer treatments may well be built.
If you care about cancer, please read studies about a new method to treat cancer effectively, and this low-dose, four-drug combo may block cancer spread.
For more information about cancer prevention, please see recent studies about nutrient in fish that can be a poison for cancer, and results showing this daily vitamin is critical to cancer prevention.
The research findings can be found in Nature Cancer.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
